Regulated
Can sell early
- Risk level
- Highest
- Risk-return
- Medium
- Start from
- €250
Funding has closed. The page stays up for reference; similar open projects are below.
IRUBIS
Germany
TU Munich BioTech on course for US Expansion: Millions in savings thanks to patented real-time monitoring in drug manufacturing.
Key figures
- Estimated return
- up to 438.84%
- platform's estimate
- Valuation
- €14,000,000
- Start from
- €250
- Target
- €1,100,000
What you own, how it can pay off, and when
How can it pay off?
The platform estimates up to 438.84%
Usually only if the company is sold or listed. Estimates are the platform's own claims.
Capital at risk. Most startups fail; estimates are the platform's own claims. Shares are hard to sell before an exit.
Would AI invest?
AI 66 MediumOur AI gives this project 66 out of 100: Medium. How the AI score works
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
AI review
AIIRUBIS GmbH — Crowdfunding Investor Memo
Real-time mid-infrared monitoring to bring biopharmaceutical drugs to market faster.
Sector: Medtech / bioprocess analytics (PAT) · Stage: Series A · HQ: Munich, Germany · Raise: €800K (of a larger Series A round)
|
|
Why this score: |
|
AI SCORE |
|
|
66 / 100 |
|
|
⭐ Moderate |
|
|
|
|
|
ℹ️ This is not investment advice. The purpose of this overview is to help potential investors preselect crowdfunding projects quickly without making a final investment decision. Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform. AI can make mistakes, so you need to double-check data. |
🏢 Company description
IRUBIS GmbH is a Munich-based medtech company and TU Munich spin-off, founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler and Anja Müller. It sells Monipa, a compact mid-infrared (MIR) spectroscopy instrument that monitors biopharmaceutical manufacturing in real time, using a patented single-use “flow cell” (the disposable part that touches the process fluid) to avoid cleaning and cross-contamination. The company reports that real-time monitoring helps drugmakers avoid losing entire production batches worth millions and shortens development timelines. As of the materials, the company reports 20 Monipa units in customer use, a published AGC Biologics case study, and more than €6m raised to date from HTGF, Verve Ventures, Ventura BioMed, EIC and BioProcess360. The business model combines one-off hardware sales (~€75k–100k per unit) with recurring consumables (~€8k/yr per unit) and software (up to ~€10k/yr). Matthias Eggers, who previously led m2p-labs to a Beckman Coulter acquisition, joined as CEO in mid-2025 to drive international scale-up. The company reports the round will fund US/Asia sales expansion and close a roughly €1.7m annual funding gap.
🎯 Potential returns
|
Target return |
Time horizon |
Target basis |
AI view on reaching this goal |
|
🎯 ~5.4x (438.84% total; 52.36%/yr) |
⏱ ~4 years |
Company-provided — the 52.36%/yr target was set by Companisto’s VC experts, labelled a target (not expected) return. |
Plausible only on a clean trade-sale at a high multiple; the target carries no disclosed exit valuation or multiple, and ~20% fees plus a 15% carry erode investor net proceeds before any of it is reached. |
📈 Path to target return
|
Company methodology |
Companisto states the target return reflects a strategic trade sale in ~4 years, valued on IP, product maturity, installed base, team and strategic fit rather than current revenue. No exit valuation, multiple, or discounted-cash-flow bridge is shown, so the 52.36%/yr figure cannot be reproduced from the materials. |
|
Comparable exits cited |
m2p-labs → Beckman Coulter / Danaher (2020) — the prior company of IRUBIS’s current CEO; a direct strategic-proximity precedent. Repligen’s PAT/TFF acquisitions (FlowVPX, Daylight QCL-IR) cited as buyer-behaviour evidence. |
|
Milestones expected |
2026: international sales build-out (USA, Asia); ~€750k one-off external-project revenue. |
|
Q2 2027: single-use filter flow-cell launch. |
|
|
2027: GMP production access. |
|
|
2028: stated exit readiness; plan turns EBITDA-positive 2029. |
💶 Valuation
|
Pre-money valuation |
€14.0M (stated fully diluted; appears bracketed/draft in the shareholders’ agreement). |
|
Post-money valuation |
~€14.8M if the full €800K Companisto round closes — but this is one slice of a larger Series A corporate round. |
|
Instrument |
Profit participation certificate (Genussrecht) issued by a Frankfurt SPV that holds IRUBIS Series A preferred shares — not direct equity. |
|
How the valuation was set |
Methodology not disclosed — no multiple, comparable set, or model is shown. |
|
External benchmarks |
None provided in the materials. |
|
Notable terms |
~20% upfront fees (10% admin + 10% brokerage) on paid-in capital; 15% carry to Companisto above a 6%/yr hurdle; no ordinary investor exit before end of FY2041. |
📜 Instrument & investor terms
What you own
You do not buy shares in IRUBIS directly. You buy a profit participation certificate (a Genussrecht — a contractual right to a share of profits and exit proceeds, not a shareholding) issued by a special-purpose vehicle (SPV), Companisto Trust Service LXIV UG in Frankfurt. That SPV owns Series A preferred shares in IRUBIS; you own a certificate over the SPV. This means there are two layers between you and the company. You have no voting rights in IRUBIS and no shareholder/membership rights; the SPV votes its shares as a single pooled block based on a prior online vote of certificate-holders, and most exit decisions are made at the shareholder level where you are not present. Certificate-holders have only narrow consent rights (for example, a sale of the SPV’s IRUBIS stake needs 75% of certificate votes).
Dilution and future rounds
This round is itself the Series A, and the company has authorised capital allowing it to issue further Series A preferred shares to new or existing investors. Crowdfund investors have no direct anti-dilution protection: the weighted-average anti-dilution clause in the shareholders’ agreement protects Series A holders (and so the SPV) only, and only in a down-round. “Dilution” simply means your slice of the company shrinks when new shares are issued.
Worked example (standard cap-table mechanics, not advice). If you invest €1,000 today at the ~€14.8M …
The full review covers the borrower or company, the security, the cash flow, the risks and a verdict. Sign in to read it.
Information, not personal investment advice. The AI score rates the documents the platform publishes, can be wrong, and does not predict returns.
Ask AI about this project
Sign in to ask the AI about this project's documents.
Sign inLike this project?
👍 Yes · 0 👎 No · 0
Comments · 0
- No comments yet.
The platform and similar projects
Offered on
Similar open projects
Kepplair Evolution
Sowefund
- Estimated return
- up to 7×
- platform's estimate
- Valuation
- €60,000,000
Raising €9m
From €500
See project
Wind Fisher
Sowefund
- Estimated return
- up to 10×
- platform's estimate
- Valuation
- €9,961,800
Raising €600k
From €1,000
See project
Blumana
Sowefund
- Estimated return
- up to 28×
- platform's estimate
- Valuation
- €2,799,571
Raising €750k
From €1,000
See project